The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.
TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.
The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.
If you have any questions you can fill in the form or mail us directly: info@train-heart.eu.
News
From 16-18 February the first hybrid TRAIN-HEART network meeting was organised by our partner: University of Porto.
The research team led by Stefan Engelhardt, Professor of Pharmacology and Toxicology at the Technical University of Munich (TUM) and Principal Investigator in the TRAIN-HEART network, has developed a new RNA drug that can prevent inflammatory lung damage. The German Federal Ministry of Education and Research (BMBF) is supporting further development of the drug as part of the TUM spin-off "rnatics" with around 7 million euros.
Great work conducted by the groups at Humanitas Mirasole (Milan, Italy) and led by Dr. Daniele Catalucci.
Two TRAIN-HEART groups teamed up (Hannover Medical School & Technical University Munich) to elucdiate the promoting role of long non-coding RNA NRON in the development of cardiac hypertrophy in the murine heart.
Hussein Genedy, TRAIN-HEART fellow at Universite Claude Bernard Lyon 1, presented his work at the 7th International Congress of the European Polysaccharide Network of Excellence (EPNOE Association)
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 813716.
Copyright © 2020
